(LFVN) Lifevantage - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US53222K2050
Stock: Supplements, Skincare, Probiotics, Nootropics, Pet Care
Total Rating 22
Risk 41
Buy Signal -0.52
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 1.65% |
| Yield on Cost 5y | 1.97% |
| Yield CAGR 5y | 24.81% |
| Payout Consistency | 75.5% |
| Payout Ratio | 28.7% |
| Risk 5d forecast | |
|---|---|
| Volatility | 129% |
| Relative Tail Risk | -7.23% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -2.00 |
| Alpha | -94.57 |
| Character TTM | |
|---|---|
| Beta | 1.122 |
| Beta Downside | 1.179 |
| Drawdowns 3y | |
|---|---|
| Max DD | 81.67% |
| CAGR/Max DD | 0.16 |
Description: LFVN Lifevantage January 17, 2026
LifeVantage Corporation (NASDAQ:LFVN) develops and markets nutrigenomic-based dietary supplements, nootropics, weight-management formulas, probiotics, and anti-aging skin-care products, selling primarily through its website and a network of independent consultants from its headquarters in Lehi, Utah.
As of its latest 10-K filing, the company reported FY 2023 revenue of roughly $30 million, a gross margin of ~55 %, and a cash position of $12 million, giving it a market capitalization of about $30 million and a net loss of $8 million, indicating a high cash-burn rate relative to its scale.
The nutraceutical sector is being driven by a projected CAGR of 8-9 % through 2028, fueled by aging demographics, increasing consumer focus on preventive health, and the shift toward e-commerce distribution-trends that directly affect LifeVantage’s growth potential and pricing power.
For a deeper, data-driven valuation, you may want to explore ValueRay’s analytical tools to assess LFVN’s risk-adjusted upside.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: 11.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.14 > 0.02 and ΔFCF/TA 5.35 > 1.0 |
| NWC/Revenue: 10.94% < 20% (prev 8.54%; Δ 2.39% < -1%) |
| CFO/TA 0.16 > 3% & CFO 10.2m > Net Income 11.4m |
| Net Debt (-1.90m) to EBITDA (17.0m): -0.11 < 3 |
| Current Ratio: 2.39 > 1.5 & < 3 |
| Outstanding Shares: last quarter (13.3m) vs 12m ago 3.71% < -2% |
| Gross Margin: 80.61% > 18% (prev 0.79%; Δ 7982 % > 0.5%) |
| Asset Turnover: 389.7% > 50% (prev 318.9%; Δ 70.79% > 0%) |
| Interest Coverage Ratio: -383.6 > 6 (EBITDA TTM 17.0m / Interest Expense TTM -36.0k) |
Altman Z'' -5.02
| A: 0.43 (Total Current Assets 45.0m - Total Current Liabilities 18.8m) / Total Assets 61.6m |
| B: -1.67 (Retained Earnings -103.1m / Total Assets 61.6m) |
| C: 0.22 (EBIT TTM 13.8m / Avg Total Assets 61.5m) |
| D: -3.68 (Book Value of Equity -104.5m / Total Liabilities 28.4m) |
| Altman-Z'' Score: -5.02 = D |
Beneish M -3.43
| DSRI: 0.67 (Receivables 2.42m/2.97m, Revenue 239.8m/196.0m) |
| GMI: 0.98 (GM 80.61% / 79.21%) |
| AQI: 0.50 (AQ_t 0.05 / AQ_t-1 0.09) |
| SGI: 1.22 (Revenue 239.8m / 196.0m) |
| TATA: 0.02 (NI 11.4m - CFO 10.2m) / TA 61.6m) |
| Beneish M-Score: -3.43 (Cap -4..+1) = AA |
What is the price of LFVN shares?
As of February 07, 2026, the stock is trading at USD 5.03 with a total of 496,306 shares traded.
Over the past week, the price has changed by -5.09%, over one month by -19.00%, over three months by -24.99% and over the past year by -73.08%.
Over the past week, the price has changed by -5.09%, over one month by -19.00%, over three months by -24.99% and over the past year by -73.08%.
Is LFVN a buy, sell or hold?
Lifevantage has received a consensus analysts rating of 5.00.
Therefore, it is recommended to buy LFVN.
- StrongBuy: 1
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the LFVN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 14.5 | 188.3% |
| Analysts Target Price | 14.5 | 188.3% |
| ValueRay Target Price | 4.4 | -12.9% |
LFVN Fundamental Data Overview February 04, 2026
P/E Trailing = 7.0641
P/S = 0.3058
P/B = 2.0302
Revenue TTM = 239.8m USD
EBIT TTM = 13.8m USD
EBITDA TTM = 17.0m USD
Long Term Debt = 11.2m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.88m USD (from shortTermDebt, last quarter)
Debt = 11.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -1.90m USD (from netDebt column, last quarter)
Enterprise Value = 68.1m USD (70.0m + Debt 11.2m - CCE 13.1m)
Interest Coverage Ratio = -383.6 (Ebit TTM 13.8m / Interest Expense TTM -36.0k)
EV/FCF = 7.83x (Enterprise Value 68.1m / FCF TTM 8.70m)
FCF Yield = 12.77% (FCF TTM 8.70m / Enterprise Value 68.1m)
FCF Margin = 3.63% (FCF TTM 8.70m / Revenue TTM 239.8m)
Net Margin = 4.78% (Net Income TTM 11.4m / Revenue TTM 239.8m)
Gross Margin = 80.61% ((Revenue TTM 239.8m - Cost of Revenue TTM 46.5m) / Revenue TTM)
Gross Margin QoQ = 80.98% (prev 79.92%)
Tobins Q-Ratio = 1.11 (Enterprise Value 68.1m / Total Assets 61.6m)
Interest Expense / Debt = 0.96% (Interest Expense 107.0k / Debt 11.2m)
Taxrate = 16.99% (710.0k / 4.18m)
NOPAT = 11.5m (EBIT 13.8m * (1 - 16.99%))
Current Ratio = 2.39 (Total Current Assets 45.0m / Total Current Liabilities 18.8m)
Debt / Equity = 0.34 (Debt 11.2m / totalStockholderEquity, last quarter 33.2m)
Debt / EBITDA = -0.11 (Net Debt -1.90m / EBITDA 17.0m)
Debt / FCF = -0.22 (Net Debt -1.90m / FCF TTM 8.70m)
Total Stockholder Equity = 30.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 18.61% (Net Income 11.4m / Total Assets 61.6m)
RoE = 37.96% (Net Income TTM 11.4m / Total Stockholder Equity 30.2m)
RoCE = 33.40% (EBIT 13.8m / Capital Employed (Equity 30.2m + L.T.Debt 11.2m))
RoIC = 34.82% (NOPAT 11.5m / Invested Capital 32.9m)
WACC = 8.77% (E(70.0m)/V(81.2m) * Re(10.05%) + D(11.2m)/V(81.2m) * Rd(0.96%) * (1-Tc(0.17)))
Discount Rate = 10.05% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.69%
[DCF Debug] Terminal Value 77.25% ; FCFF base≈7.37m ; Y1≈8.38m ; Y5≈11.5m
Fair Price DCF = 13.60 (EV 170.9m - Net Debt -1.90m = Equity 172.8m / Shares 12.7m; r=8.77% [WACC]; 5y FCF grow 16.00% → 2.90% )
EPS Correlation: 44.58 | EPS CAGR: -21.14% | SUE: -2.31 | # QB: 0
Revenue Correlation: 40.65 | Revenue CAGR: 3.06% | SUE: 0.19 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.39 | Chg30d=+0.092 | Revisions Net=+1 | Analysts=3
EPS current Year (2026-06-30): EPS=1.05 | Chg30d=+0.032 | Revisions Net=+1 | Growth EPS=+27.6% | Growth Revenue=-0.4%
EPS next Year (2027-06-30): EPS=1.22 | Chg30d=+0.102 | Revisions Net=+1 | Growth EPS=+16.2% | Growth Revenue=+7.0%
P/S = 0.3058
P/B = 2.0302
Revenue TTM = 239.8m USD
EBIT TTM = 13.8m USD
EBITDA TTM = 17.0m USD
Long Term Debt = 11.2m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.88m USD (from shortTermDebt, last quarter)
Debt = 11.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -1.90m USD (from netDebt column, last quarter)
Enterprise Value = 68.1m USD (70.0m + Debt 11.2m - CCE 13.1m)
Interest Coverage Ratio = -383.6 (Ebit TTM 13.8m / Interest Expense TTM -36.0k)
EV/FCF = 7.83x (Enterprise Value 68.1m / FCF TTM 8.70m)
FCF Yield = 12.77% (FCF TTM 8.70m / Enterprise Value 68.1m)
FCF Margin = 3.63% (FCF TTM 8.70m / Revenue TTM 239.8m)
Net Margin = 4.78% (Net Income TTM 11.4m / Revenue TTM 239.8m)
Gross Margin = 80.61% ((Revenue TTM 239.8m - Cost of Revenue TTM 46.5m) / Revenue TTM)
Gross Margin QoQ = 80.98% (prev 79.92%)
Tobins Q-Ratio = 1.11 (Enterprise Value 68.1m / Total Assets 61.6m)
Interest Expense / Debt = 0.96% (Interest Expense 107.0k / Debt 11.2m)
Taxrate = 16.99% (710.0k / 4.18m)
NOPAT = 11.5m (EBIT 13.8m * (1 - 16.99%))
Current Ratio = 2.39 (Total Current Assets 45.0m / Total Current Liabilities 18.8m)
Debt / Equity = 0.34 (Debt 11.2m / totalStockholderEquity, last quarter 33.2m)
Debt / EBITDA = -0.11 (Net Debt -1.90m / EBITDA 17.0m)
Debt / FCF = -0.22 (Net Debt -1.90m / FCF TTM 8.70m)
Total Stockholder Equity = 30.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 18.61% (Net Income 11.4m / Total Assets 61.6m)
RoE = 37.96% (Net Income TTM 11.4m / Total Stockholder Equity 30.2m)
RoCE = 33.40% (EBIT 13.8m / Capital Employed (Equity 30.2m + L.T.Debt 11.2m))
RoIC = 34.82% (NOPAT 11.5m / Invested Capital 32.9m)
WACC = 8.77% (E(70.0m)/V(81.2m) * Re(10.05%) + D(11.2m)/V(81.2m) * Rd(0.96%) * (1-Tc(0.17)))
Discount Rate = 10.05% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.69%
[DCF Debug] Terminal Value 77.25% ; FCFF base≈7.37m ; Y1≈8.38m ; Y5≈11.5m
Fair Price DCF = 13.60 (EV 170.9m - Net Debt -1.90m = Equity 172.8m / Shares 12.7m; r=8.77% [WACC]; 5y FCF grow 16.00% → 2.90% )
EPS Correlation: 44.58 | EPS CAGR: -21.14% | SUE: -2.31 | # QB: 0
Revenue Correlation: 40.65 | Revenue CAGR: 3.06% | SUE: 0.19 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.39 | Chg30d=+0.092 | Revisions Net=+1 | Analysts=3
EPS current Year (2026-06-30): EPS=1.05 | Chg30d=+0.032 | Revisions Net=+1 | Growth EPS=+27.6% | Growth Revenue=-0.4%
EPS next Year (2027-06-30): EPS=1.22 | Chg30d=+0.102 | Revisions Net=+1 | Growth EPS=+16.2% | Growth Revenue=+7.0%